Adalimumab biosimilar - Mabpharm
Alternative Names: CMAB 815Latest Information Update: 28 Sep 2022
At a glance
- Originator Sinomab
- Developer Mabpharm
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China (SC, Injection)
- 28 Aug 2018 Preclinical trials in Rheumatoid arthritis in China (SC)
- 28 Aug 2018 Mabpharm expects clinical trial approval from China FDA in Rheumatoid arthritis by the end of 2018